📄 What This Document Is

This is an 8-K filing, which is like a company's "breaking news" update to the SEC and investors. PAVmed Inc. (ticker: PAVM) is using it to give a big picture update on its business and report its financial results for the fourth quarter and full year of 2025. Think of it as a progress report mixed with a financial statement.

🏢 What The Company Does

👉 In simple terms, PAVmed is a medical technology "holding company" that builds and runs businesses focused on medical devices, cancer diagnostics, and digital health tools for cancer care. They operate through subsidiaries, like a parent company overseeing specialized kids.

Lucid Diagnostics (LUCD): Sells tests (EsoGuard/EsoCheck) to detect esophageal cancer early.
Veris Health: Is building an implantable health monitor and a connected cancer care platform.
PAVmed Direct: Handles its own medical device portfolio.

💰 Financial Highlights

Here’s the money snapshot for Q4 2025 (the last 3 months of 2025):

Revenue: $52,000. This is very low, showing the subsidiaries are still in early commercial stages.
Net Loss (GAAP): A loss of $1.8 million, or $(2.05) per share. This includes a lot of accounting adjustments.
"Real Operational" Loss (Non-GAAP): When you strip out non-cash items like stock compensation, the adjusted loss was about $942,000, or $(1.05) per share.
Cash on Hand: $1.5 million as of Dec. 31, 2025. This is a key number to watch.

👉 Why it matters: The company is spending much more than it's making in revenue, which is common for growth-stage medical tech firms. The non-GAAP number helps show the cash cost of running the business day-to-day.

🚀 Key Moves & Corporate Actions

PAVmed made several big moves to clean up its finances and set up for growth:

Strengthened the Bank Account: Raised $30 million by selling special "Series D" preferred stock and got a $15 million loan.
Cleared Old Debts: Used this new money to pay off all its complicated "convertible securities," which were a legacy headache. This simplifies the company structure.
Relaunched Medical Devices: Appointed Joseph Virgilio as Chief Business Officer to lead its device portfolio, including the PortIO vascular access device and a new imaging tech licensed from Duke University.

🤝 Subsidiary Spotlight: Veris Health

Veris is making progress on two fronts:

Partnership with Ohio State (OSU): Its strategic partnership with The Ohio State University's James Cancer Hospital is now in the "commercial phase," and its software is fully integrated with the hospital's records system.
Implantable Monitor: It's developing an implantable physiological monitor (like a smart sensor) and plans to seek FDA approval (510(k) submission) in late 2026.

🔬 Subsidiary Spotlight: Lucid Diagnostics

Lucid is focused on expanding access to its cancer tests:

Medicare Coverage in Sight: It's approaching a pivotal decision for Medicare coverage of its EsoGuard test, which could be transformative for sales.
VA Contract Win: Secured a contract to supply EsoGuard to the U.S. Veterans Affairs system, potentially reaching ~9 million veterans.
Clinical Evidence: Published real-world data on nearly 12,000 patients supporting the test's effectiveness.

📦 Financial Position & Funding

The company's financial health changed significantly:

New Cash, Less Complexity: The $45 million in total new funding (stock + debt) extends its "cash runway"—meaning how long it can operate before needing more money. Paying off old convertible debt removes potential future dilution for shareholders.
Warrants in Play: As part of the Series D deal, $30 million in warrants were issued. These can be "called" (essentially forced exercise) if a draft Medicare coverage policy for EsoGuard is published, which could bring in more cash.

🔮 What's Next

The roadmap is clear:

For Veris: Advance the implantable monitor toward that late 2026 FDA submission.
For Lucid: Await and hopefully secure favorable Medicare coverage for EsoGuard, which would be a major revenue catalyst.
For PAVmed: Continue executing as a "shared services" model, supporting its now better-capitalized subsidiaries.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

Cleaned-Up Balance Sheet: Removing legacy convertible debt is a major positive, reducing complexity and future share dilution risk.
Clear Subsidiary Strategy: Each business (Lucid, Veris, Devices) can now focus on its own milestones.
Near-Term Catalysts: FDA submission for Veris and Medicare decision for Lucid are significant upcoming value drivers.

⚠️ Risks:

Low Cash & High Burn: $1.5 million in cash is very low. The company is still losing money and will likely need to raise more capital soon.
Execution Risk: Success depends on hitting clinical, regulatory, and commercial milestones at all three entities.
No Revenue at Scale: The core diagnostics business has minimal revenue, and the device portfolio is being relaunched.

🧠 The Analogy

Think of PAVmed like a renovation company that just finished fixing the foundation (balance sheet) and has now handed the keys to three specialized crews (Lucid, Veris, Devices) to build out their sections of the house. The foundation work took time and money, but now the real building can begin. The big question is whether they have enough fuel (cash) in the tank to finish the job.

📇 Key Contacts & People

Matt Riley: Contact for PAVmed and Lucid Diagnostics.
Email: [email protected]
Conference Call: Access details provided in the filing for the call on March 30, 2026.

🧩 Final Takeaway

PAVmed has successfully restructured its complex finances and is now a simpler, better-funded parent company for three medical tech businesses. The story shifts from financial repair to execution, with its future hinging on FDA and Medicare decisions in 2026.

PAVmed Inc. — 8-K Filing